The Interactions of Nintedanib and Oral Anticoagulants—Molecular Mechanisms and Clinical Implications
Open Access
- 30 December 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (1), 282
- https://doi.org/10.3390/ijms22010282
Abstract
Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and vascular endothelial growth factor families. The drug also affects other kinases, including Src, Flt-3, LCK, LYN. Nintedanib is used in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases and lung cancer. The mechanism of action suggests that nintedanib should be considered one of the potential agents for inhibiting and revising the fibrosis process related to COVID-19 infections. Due to the known induction of coagulation pathways during COVID-19 infections, possible interaction between nintedanib and anticoagulant seems to be an extremely important issue. In theory, nintedanib could increase the bleeding risk, thrombosis and lead to thrombocytopenia. The data from clinical trials on the concomitant use of nintedanib and antithrombotic agents is very limited as this patient group was within the standard exclusion criteria. Nintedanib is an important therapeutic option, despite its interaction with anticoagulants. If anticoagulant therapy is necessary, the more effective and safer option is the concomitant administration of DOACs and nintedanib, especially when drug-monitored therapy will be used in patients at high risk of bleeding complications.This publication has 86 references indexed in Scilit:
- How Does a Drug Molecule Find Its Target Binding Site?Journal of the American Chemical Society, 2011
- Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteersXenobiotica, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblastsArthritis & Rheumatism, 2009
- Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranAmerican Heart Journal, 2009
- Novel Agents on the Horizon for Cancer TherapyCA: A Cancer Journal for Clinicians, 2009
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor EfficacyCancer Research, 2008
- Tyrosine Kinases as Targets for Cancer TherapyThe New England Journal of Medicine, 2005
- THE CROONIAN LECTURE 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and diseasePhilosophical Transactions B, 1998
- Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with InhibitorsScience, 1997